The Supreme Court is poised to decide one of the most consequential questions in pharmaceutical patent law: when does a generic drug’s marketing create skinny label patent infringement liability?
On January 16, 2026, the Court granted certiorari in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. (No. 24-889) — its first patent case in nearly three years — with oral argument set for April 29, 2026.
- When a generic drug label fully carves out a patented use, are allegations that the generic drugmaker calls its product a “generic version” and cites public information about the branded drug (e.g., sales) enough to plead induced infringement of the patented use?
- Does a complaint state a claim for induced infringement of a patented method if it does not allege any instruction or other statement by the defendant that encourages, or even mentions, the patented use?
Background: Vascepa and the Hatch-Waxman Skinny Label
Amarin Pharma markets icosapent ethyl under the brand name “Vascepa,” a drug initially approved by the FDA in 2012 for treating severe hypertriglyceridemia. Following successful additional clinical trials, the FDA approved Vascepa in 2019 for a second use: reducing cardiovascular risk in certain patient populations. Amarin obtained method of use patents, Nos. 9,700,537 and 10,568,861, covering that cardiovascular indication.
Under the Hatch-Waxman Act, a generic manufacturer can file a “section viii statement” carving patented methods of use out of its proposed label and seeking FDA approval only for the unpatented uses, otherwise known as a “skinny label.” The “skinny label” was designed to ensure “that one patented use will not foreclose marketing a generic drug for other unpatented ones.” Hikma followed this process, obtained FDA approval for a label covering only the unpatented hypertriglyceridemia indication, and launched its generic product in November 2020.
The district court dismissal
Amarin sued Hikma in the District of Delaware, alleging induced infringement of its cardiovascular patents under 35 U.S.C. § 271(b). The district court dismissed the suit, concluding as a matter of law that a label’s silence on the patented use is not the same as recommending or promoting it.
The Federal Circuit’s ruling on skinny label patent infringement
On June 25, 2024, the Federal Circuit reversed, holding that the totality of Hikma’s conduct, label and public statements together, plausibly stated a claim for induced infringement. The panel pointed to Hikma’s press releases, which consistently referred to its product as the “generic version of Vascepa” and referenced Vascepa’s overall sales figures without distinguishing between the unpatented and patented uses. Amarin alleged that the vast majority of those sales, reportedly over 90%, were attributable to the patented cardiovascular indication, and that Hikma was aware of this. The Federal Circuit further held that what Hikma’s statements communicated to physicians is a question of fact, not law, and cannot be resolved on a motion to dismiss. The court denied en banc rehearing in October 2024.
This ruling follows the Federal Circuit’s 2021 decision in GlaxoSmithKline LLC v. Teva Pharms. USA, Inc., 7 F.4th 1320 (Fed. Cir. 2021), which affirmed a jury verdict of induced infringement against a generic manufacturer that had carved out the relevant indication from its label. The Solicitor General urged the Court to grant certiorari in GSK as well, but the Court denied review. Hikma asserts it presents a “much better vehicle than GSK”: unlike in GSK, where the partial label was alleged to instruct the patented method of use, here it is undisputed that Hikma’s label contains no instruction, mention, or encouragement of the patented use whatsoever.
The Arguments on Each Side
Hikma: passive conduct is not active inducement
Hikma argues the Federal Circuit “effectively read the word ‘actively’ out of the Patent Act, replacing it with the precise opposite word, ‘passively.'” Under 35 U.S.C. § 271(b), liability attaches only to whoever “actively induces” infringement, a standard requiring “the taking of affirmative steps to bring about” the infringing act. What Amarin is really describing, Hikma argues, is passive inducement: a physician infers from the words “generic version” that the product can be used for all of Vascepa’s approved indications, then consults Amarin’s own label to learn how. That chain of inference is not the active encouragement the statute requires.
Hikma also argues Amarin’s inducement theory is factually implausible. The press releases Amarin relies on were directed to investors, mentioned only the unpatented hypertriglyceridemia indication, never used the word “cardiovascular,” and had been removed from Hikma’s website before the product even launched. When Hikma actually launched, its press release explicitly stated the product was “not approved for any other indication for the reference listed drug VASCEPA.” And the asserted patents require co-administration with a statin, something none of Hikma’s accused statements mention, meaning they could not have induced all steps necessary to infringe regardless.
Because every generic is by definition a “generic version” of a branded drug and discussing market size is routine in any industry, the decision below means no skinny label is ever safe. The section viii pathway becomes economically untenable, Hikma warns, especially since an inducement claim, unlike a standard Hatch-Waxman suit, can expose a generic to trebled lost-profits damages.
Amarin: this case is about marketing choices, not the label
Amarin urges affirmance, arguing this case is not about the skinny label, it is about Hikma’s own marketing choices. Seven other manufacturers sell generic icosapent ethyl under materially identical skinny labels; Amarin has sued none of them. Hikma alone chose to describe its product under the broad category of “Hypertriglyceridemia” on its website, a category that encompasses the patented cardiovascular use, and publicized nearly a billion dollars in total Vascepa sales knowing that Vascepa’s commercial identity was built around its cardiovascular indication. Hikma also omitted a “limitation of use” from its label that would have made clear the cardiovascular effects of the drug had not been evaluated, a choice, Amarin argues, that was not required by Hatch-Waxman.
Amarin further disputes that the press releases were purely investor-directed, arguing that physicians in fact consult such statements when assessing a generic drug’s uses. And even if the Court found the current complaint insufficient, Amarin argues it would be entitled to amend, because fact discovery has since uncovered substantial additional evidence of active inducement.
What the Decision Means for Generic Drug Makers
The Hikma v. Amarin decision will have immediate implications for generic drug launch strategy, labeling, and litigation risk:
- A ruling for Hikma would reinforce the section viii carve-out pathway and establish that routine generic marketing statements cannot support an inducement claim.
- A ruling for Amarin would confirm that branded companies can pursue inducement claims against skinny-label generics based on the totality of public statements, requiring generic manufacturers to scrutinize every press release, investor call, and marketing communication for any reference that could be read as encouraging a carved-out use.
- Either way, the decision will define the boundaries of “actively induces” under § 271(b) in the pharmaceutical context.
However the Court rules, Hikma v. Amarin will define the boundaries of skinny label patent infringement liability for every generic manufacturer relying on the section viii pathway — and a decision is expected before the Court’s summer recess in early July 2026.